**Description**

**A FORMULATION INTENDED TO HAVE ANTI-CARCINOGENIC EFFECT BY STIMULATING BAX EXPRESSION**

**Field of Invention**

The present invention herewith is related to a formulation that has an anti-carcinogenic effect by stimulating bax expression.

**Background of the Related Technology**

At present it is known that an anti-carcinogenic substance is any agent that prevents the development of cancer or prevents the growth of tumor. Bax or Bcl-2-associated X protein, is a protein existing in the human body, which has the function of being the co-factor of a tumor suppressing protein called p53. Bax gene is a member of the Bcl-2 gene family. Bax, is induced by p53 mediation and accelerates progress of the cell towards apoptosis. Reduced Bax formation is a sign of bad prognosis in oral cavity cancers.

In state of art technology, invention no EP2307002B1, with title "DNA Methyltransferase Inhibitors like Decitabin and Prokain with Sapacitabine or cndac Combinations” and under classification number "A61K 31/245", discloses a pharmaceutical combination that is suitable for treatment of cancer and other proliferative disorders.

Again invention no EP1443942B1, with title and "A Pharmaceutical Composition that Contains a Bisphosphanate, a cox-2 Inhibitor and a Taxol and is Used in Treatment of Malignant Diseases”, discloses a pharmaceutical composition that contains a bisphosphonate, a COX-2 inhibitor and a taxol or derivatives of these for treatment of prostate cancer, multiple myeloma (MM), Tumor Related Hypertension (TIH), breast cancer, lung cancer and bone metastasis (BM) related to prostate cancer or colon cancer.

Again invention no EP1299350B1, with title "Substituted Benzamides for Enhancing Immunity and Treatment of Cancer, Infection and Manic Depressive Diseases” discloses substituted benzamides that include transcription factor AP (protein activator) -1 developers in the compositions including the referred compound thereof and also discloses the methods used for clinical treatment of diseases that are related to cases, which suppress the immune system and also to using the benzamides for preparing the drug for the purpose of stimulating the transcription factor AP-1. These types of compounds are particularly useful in treatment of various diseases that suppress the immune system and are related to low production rate of IL (interleukin)-2. Diseases included in this group are cancers, autoimmune diseases and infectious diseases. Particularly, the referred invention discloses benzamides that are suitable for treatment of solid tumors and diseases like rheumatoid arthritis (RA) and AIDS. The compounds of the referred invention are also suitable for the treatment of manic depressive diseases.

To conclude it has become inevitable to proceed with a development in the area of the related technology, considering the inadequacy of the existing solutions and the need for a formulation that has an anti-carcinogenic effect by stimulating bax expression

**Objective of the Invention**

To overcome the disadvantages experienced in state of art technology;

* One objective of the present invention is to increase bax expression.

The present invention which is aimed to achieve the above-mentioned advantages, is related to a formulation that has an anti-carcinogenic effect by stimulating bax expression and is a formulation that is obtained by combination of the compositions selected in a single form or in combinations from a group containing; (3β,5β)-19,20-trimethoxydamar-24-ene-3-coumaroyl 2-*O*-β-D-hexapyranosyl-β-D-diethylpyranoside, (3β,10β)-12,20-hexahydroxydamar-20-ene-4-caffeoyl 7-*O*-β-D-glucopyranosyl-β-D-trihydroxypyranoside.

Structural and characteristic properties as well as all the advantages of the invention presented herewith will be clearly understood with the detailed description provided below and thus the evaluation regarding the present invention should be based on the detailed description presented herewith.

**Detailed Description of the Invention**

The present invention is related to a formulation that has an anti-carcinogenic effect by stimulating bax expression. Referred formulation increases bax expression.

The formulation of the invention presented herewith contains; (3β,5β)-19,20-trimethoxydamar-24-ene-3-coumaroyl 2-*O*-β-D-hexapyranosyl-β-D-diethylpyranoside, (3β,10β)-12,20-hexahydroxydamar-20-ene-4-caffeoyl 7-*O*-β-D-glucopyranosyl-β-D-trihydroxypyranoside .

The referred formulation is formed by mixing the above-mentioned components at below percentages by weight;

* 1-99% of (3β,5β)-19,20-trimethoxydamar-24-ene-3-coumaroyl 2-*O*-β-D-hexapyranosyl-β-D-diethylpyranoside,
* 99-1% of (3β,10β)-12,20-hexahydroxydamar-20-ene-4-caffeoyl 7-*O*-β-D-glucopyranosyl-β-D-trihydroxypyranoside.

Components given above are obtained by combining the components from the above-mentioned group at the given range of weight ratios in a single form or in combinations thereof.

The present invention herewith is also related to using the referred composition thereof to have an anti-carcinogenic effect by stimulating bax expression and also to manufacture the referred composition for such purpose.

**CLAIMS**

1. A formulation intended having an anti-carcinogenic effect by stimulating bax expression and which consists of combining the components selected from the group; (3β,5β)-19,20-trimethoxydamar-24-ene-3-coumaroyl 2-*O*-β-D-hexapyranosyl-β-D-diethylpyranoside, (3β,10β)-12,20-hexahydroxydamar-20-ene-4-caffeoyl 7-*O*-β-D-glucopyranosyl-β-D-trihydroxypyranoside in a single form or in combinations thereof.
2. The formulation of Claim 1 which is characterized by containing 1-99% of (3β,5β)-19,20-trimethoxydamar-24-ene-3-coumaroyl 2-*O*-β-D-hexapyranosyl-β-D-diethylpyranoside by weight.
3. The formulation of Claim 1 which is characterized by containing 99-1% of (3β,10β)-12,20-hexahydroxydamar-20-ene-4-caffeoyl 7-*O*-β-D-glucopyranosyl-β-D-trihydroxypyranoside by weight.
4. Using the compositions obtained by selecting singly or in combination of components from the group of; (3β,5β)-19,20-trimethoxydamar-24-ene-3-coumaroyl 2-*O*-β-D-hexapyranosyl-β-D-diethylpyranoside, (3β,10β)-12,20-hexahydroxydamar-20-ene-4-caffeoyl 7-*O*-β-D-glucopyranosyl-β-D-trihydroxypyranoside from any one as given in Claims 2-3 in manufacturing the formulation intended having an anti-carcinogenic effect by stimulating bax expression.

**SUMMARY**

**A FORMULATION INTENDED TO HAVE ANTI-CARCINOGENIC EFFECT BY STIMULATING BAX EXPRESSION**

The present invention is related to a formulation that has an anti-carcinogenic effect by stimulating bax expression. Referred formulation increases bax expression.

There are no illustrations.